Price alert —
Sign in to get a one-time email the moment CDT crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · CDT
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare CDT vs peers
Line CDT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
CDT
CDT Equity Inc.
$0.31
-11.83%
MSFT
MSFT
$393.82
-1.82%
META
META
$646.01
-2.79%
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| CDT ★ | $0B | — | — | — | -0.1 | -0.0 | — | — | — | 9088.49% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 0.16%
| Holder | Shares | % out |
|---|---|---|
| Financial Management Professionals, | 10,005 | 0.16% |
| Tower Research Capital LLC (TRC) | 110 | — |
| Morgan Stanley | 2 | — |
Insider activity · 90d
1 buys / 4 sells · ratio 0.25 · Finnhub
- Taylor Mark Andrew SELL 0 @ $1.40
- Taylor Mark Andrew SELL 593,289 @ $0.75
- Taylor Mark Andrew SELL 0 @ $1.44
- Taylor Mark Andrew SELL 1,464,711 @ $0.71
- Regan Andrew BUY 256,393 @ $1.90
Analyst estimates
yfinanceWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
Consensus: none (mean None). Distribution requires FINNHUB_API_KEY.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-16 | 8-K | view · |
| 10-Q | 2026-07-15 | 10-Q | view · |
| 8-K | 2026-07-07 | 8-K | view · |
| 8-K | 2026-06-29 | 8-K | view · |
| 4 | 2026-06-23 | Insider transaction (Form 4) | view · |
| 8-K | 2026-06-16 | 8-K | view · |
| 8-K | 2026-05-28 | 8-K | view · |
| 8-K | 2026-05-15 | 8-K | view · |
| 4 | 2026-05-14 | Insider transaction (Form 4) | view · |
| 8-K | 2026-04-27 | 8-K | view · |
| 10-K | 2026-04-15 | 10-K | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 8-K | 2026-03-25 | 8-K | view · |
| 8-K | 2026-03-18 | 8-K | view · |
| 8-K | 2026-03-09 | 8-K | view · |
| DEF 14A | 2026-03-06 | DEF 14A | view · |
| 8-K | 2026-02-24 | 8-K | view · |
| 4 | 2026-02-23 | 4 | view · |
| 8-K | 2026-01-22 | 8-K | view · |
| 8-K | 2026-01-02 | 8-K | view · |
| 4 | 2025-12-22 | 4 | view · |
| 8-K | 2025-12-12 | 8-K | view · |
| 10-Q | 2025-11-13 | 10-Q | view · |
| 8-K | 2025-10-09 | 8-K | view · |
| 4 | 2025-09-22 | Insider transaction (Form 4) | view · |
| 4 | 2025-09-19 | Insider transaction (Form 4) | view · |
| 4 | 2025-08-26 | 4 | view · |
| 4 | 2025-08-26 | 4 | view · |
| 4 | 2025-08-26 | 4 | view · |
| 10-Q | 2025-08-14 | 10-Q | view · |
| 8-K | 2025-08-14 | 8-K | view · |
| 8-K | 2025-08-08 | 8-K | view · |
| DEF 14A | 2025-07-08 | DEF 14A | view · |
| 4 | 2025-06-13 | Insider transaction (Form 4) | view · |
| 8-K | 2025-06-09 | 8-K | view · |
| 8-K | 2025-06-03 | 8-K | view · |
| 8-K | 2025-05-16 | 8-K | view · |
| 10-Q | 2025-05-15 | 10-Q | view · |
| 8-K | 2025-05-06 | 8-K | view · |
| DEF 14A | 2025-04-25 | Proxy statement | view · |
| 8-K | 2025-04-25 | Material event (8-K) | view · |
| 4 | 2025-04-17 | Insider transaction (Form 4) | view · |
| 8-K | 2025-04-16 | Material event (8-K) | view · |
| 8-K | 2025-04-04 | Material event (8-K) | view · |
| 4 | 2025-04-01 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-01 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-01 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-01 | Insider transaction (Form 4) | view · |
| 8-K | 2025-04-01 | Material event (8-K) | view · |
| 10-K | 2025-03-28 | Annual report (10-K) | view · |
| 8-K | 2025-03-06 | Material event (8-K) | view · |
| 8-K | 2025-02-19 | Material event (8-K) | view · |
| 8-K | 2025-02-11 | Material event (8-K) | view · |
| 8-K | 2025-01-23 | Material event (8-K) | view · |
| 8-K | 2025-01-14 | Material event (8-K) | view · |
| 4 | 2024-12-20 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-20 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-20 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-20 | Insider transaction (Form 4) | view · |
| 8-K | 2024-12-20 | Material event (8-K) | view · |
About CDT
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Options picks · CDT
ITM + OTM ideas from the latest scanLoading…
Congress trades · CDT
STOCK Act disclosuresLoading…
SEC filings & insiders · CDT
EDGAR · liveLoading…
Holders · CDT
Institutions & insider activityLoading…